Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.
By N. Shinojima, K. Tada, Shoji Shiraishi, T. Kamiryo, M. Kochi, Hideo Nakamura, K. Makino, H. Saya, H. Hirano, J. Kuratsu and 3 more. Cancer Research, 2003
689 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/dd0cad23838cffe6ab33c4e19bb77aabbd7aa4a9
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- H. Ohgaki
- P. Kleihues
- P. Delgado-López
- Kenneth D. Aldape
- E. Corrales-García
- Q. Ostrom
- Guido Reifenberger
- Jigisha P. Thakkar
Citations in the corpus
- Glioblastoma: pathology, molecular mechanisms and markers (2015, background): “The EGFRvIII mutation involves an intragenic gene rearrangement that is generated by an in-frame deletion of exons 2–7, which encode part of the extracellular domain of this protein [40, 62, 147].”
- Survival in glioblastoma: a review on the impact of treatment modalities (2016, background): “found EGFR amplification to be an independent, unfavorable predictor for overall survival [87].”
- Epidemiologic and Molecular Prognostic Review of Glioblastoma (2014, background): “EGFRvIII over-expression was found to be a strong predictor of poor prognosis in presence of EGFR amplification (123).”
- Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. (2005, background): “Several studies have suggested that EGFR amplification is predictive for certain age groups of glioblastoma patients (34, 37, 42, 43).”
- Genetic Pathways to Glioblastoma (2004, background): “(33) reported that EGFR amplification was a significant unfavorable predictor for overall survival in glioblastoma patients and that the EGFR gene status was a more significant prognostic factor in younger patients ( 60 years).”
- Current Challenges and Opportunities in Treating Glioblastoma (2018, background): “Another gene therapy that has reached clinical trials is SGT-94, which contains RB94 plasmid DNA that encodes a truncated form of the RB gene, in a liposome with an antitransferrin receptor antibody (Siefker-Radtke et al., 2016).”